BTBD18 Activators

BTBD18 Activators consist of various compounds that indirectly influence the functional activity of BTBD18, primarily through their effects on protein ubiquitination and degradation pathways. Proteasome inhibitors such as MG132, Bortezomib, Velcade, Epoxomicin, and Lactacystin are particularly significant, as they can modulate BTBD18's activity within the ubiquitin-proteasome system. This modulation is critical for BTBD18's involvement in protein quality control, degradation, and cellular stress responses. The influence of these inhibitors highlights the potential role of BTBD18 in managing protein turnover and maintaining cellular homeostasis.

Compounds like Thalidomide and its derivatives, Lenalidomide and Pomalidomide, also play a crucial role by modulating the ubiquitin-proteasome pathway. These compounds might enhance BTBD18's function in protein regulation, impacting various cellular processes, including cell cycle regulation and stress response mechanisms. Curcumin, known for its broad biological activities, could further modulate BTBD18's activity by influencing protein degradation pathways, enhancing its role in cell regulation and signaling. Additionally, inhibitors of peptidyl-prolyl cis-trans isomerases, which affect protein folding, could indirectly influence BTBD18 if it is associated with pathways related to protein conformation and stability. Chloroquine, by affecting lysosomal function and autophagy, might also impact BTBD18's function in protein degradation, potentially enhancing its role in cellular stress mechanisms. Moreover, MLN4924 (Pevonedistat), an inhibitor of the NEDD8-activating enzyme, could indirectly affect BTBD18's function in ubiquitination and degradation pathways, highlighting its potential role in cell cycle control and response to cellular stress.